Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

This is a multicenter, single-arm phase II trial evaluating the efficacy and safety of an immune-sensitizing strategy with temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab in patients with microsatellite-stable (MSS) and O(6)-methylguanine–DNA methyltransferase (MG...

Descripción completa

Detalles Bibliográficos
Autores principales: Morano, Federica, Raimondi, Alessandra, Pagani, Filippo, Lonardi, Sara, Salvatore, Lisa, Cremolini, Chiara, Murgioni, Sabina, Randon, Giovanni, Palermo, Federica, Antonuzzo, Lorenzo, Pella, Nicoletta, Racca, Patrizia, Prisciandaro, Michele, Niger, Monica, Corti, Francesca, Bergamo, Francesca, Zaniboni, Alberto, Ratti, Margherita, Palazzo, Michele, Cagnazzo, Celeste, Calegari, Maria Alessandra, Marmorino, Federica, Capone, Iolanda, Conca, Elena, Busico, Adele, Brich, Silvia, Tamborini, Elena, Perrone, Federica, Di Maio, Massimo, Milione, Massimo, Di Bartolomeo, Maria, de Braud, Filippo, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084437/
https://www.ncbi.nlm.nih.gov/pubmed/35258987
http://dx.doi.org/10.1200/JCO.21.02583

Ejemplares similares

Ejemplares similares